GLP-1 Peptide Atlas, by Delfa

← Trials/Trial dossier/NCT02577848

UnknownPhase NA

GLP-1 on Non-ST-Segment Elevation Myocardial Infarction

Effects of Liraglutide on Left Ventricular Function in Patients With Non-ST-Segment Elevation Myocardial Infarction

Lead sponsor

Chinese PLA General Hospital

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Enrollment

estimated

Study population

Cardiovascular disease

Key I/E criterion

—

Primary endpoint

•Left ventricular ejection fractions

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT02577848

Org study IDGLP-1-301xnk

Timeline

Milestones

Study first posted2015-10-16estimated

Last update posted2015-10-19estimated

Study start2015-10 (month precision)

Primary completion2016-10estimated (month precision)

Study completion2016-10estimated (month precision)

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Cardiovascular disease

Eligibility

Who can enroll

Minimum age18 Years

Maximum age80 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

non-ST-segment elevation myocardial infarction (NSTEMI )

Exclusion criteria

1. unconscious at presentation

2. had ST-segment elevation acute myocardial infarction

3. NSTEMI requiring emergency percutaneous coronary angiography

4. valvular heart disease

5. cardiogenic shock

6. hypoglycaemia

7. diabetic ketoacidosis

8. had a history of myocardial infarction

9. stent implantation

10. renal insufficiency

11. had previously undergone coronary artery bypass surgery.

Endpoints (3)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Heart failure

Safety / tolerability / PK

Heart failure

2 endpoints

Primary/protocol endpoint

left ventricular ejection fractions

Time frame:at 3 months

change from baseline, improvement

Secondary/protocol endpoint

6-minute walk distance

Time frame:at 3 months

6-minute walk distance

change from baseline, improvement

Safety / tolerability / PK

1 endpoint

Secondary/protocol endpoint

treatment-emergent adverse events

Time frame:at 3 months

Treatment-emergent AEs (any)

event count, event

Publications (5)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes.
The New England journal of medicine2013 Sep 12PMID23991622doi:10.1056/NEJMoa1308075via CT.gov background
Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes.
Diabetes care2013 Aug (month)PMID23564922doi:10.2337/dc12-2469via CT.gov background
Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction.
European heart journal2012 Jun (month)PMID21920963doi:10.1093/eurheartj/ehr309via CT.gov background
Fasting glucose in acute myocardial infarction: incremental value for long-term mortality and relationship with left ventricular systolic function.
Diabetes care2007 Apr (month)PMID17392556doi:10.2337/dc06-1735via CT.gov background
Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines.
The Journal of pharmacology and experimental therapeutics2005 Jan (month)PMID15356213doi:10.1124/jpet.104.073890via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.